




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Agrawal, Sudhir
Serial No.: 09/103,745 Examiner: James Schultz
Filed: June 24, 1998 Group Art Unit: 1635
For: **Method for Using Oligonucleotides Having Modified CpG Dinucleotides**
Atty. Docket No.: 47508.642 HYZ-642

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on April 6, 2004.


Tina M. Dougal

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97-98, and M.P.E.P. §609, Applicants hereby enclose Form PTO-1449 that includes publications that have previously been cited in a prior patent application Serial No. 08/711,568 filed on September 10, 1996, now issued under U.S. Patent No. 5,856,462 from which the above application claims priority under 35 U.S.C. §120.

With the exception of the following publications identified below, pursuant to 37 C.F.R. § 1.98(d), no further copies of the previously cited art are enclosed.

Enclosed Publications

- Boggs, R, et al., "Characterization and Modulation of Immune Stimulation by Modified Oligonucleotides", ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, Vol. 7, October 1997, pp. 461-471.
- Kandimalla, E., et al., "Mixed backbone antisense oligonucleotides: design, biochemical and biological properties of oligonucleotides containing 2'-5'-ribo-and 3'-5'-deoxyribonucleotide segments", NUCLEIC ACIDS RESEARCH, 1997, Vol. 25, No. 2, pp. 370-378.
- Zhao, Q., et al., "Pattern and Kinetics of Cytokine Production Following Administration of Phosphorothioate Oligonucleotides in Mice", ANTISENSE AND NUCLEIC ACID DRUG DEVELOPMENT, 7: 495-502 (1997).


It is respectfully requested that the information above be expressly considered and that the publications be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

As this paper is being filed prior to the issuance of a first Office Action on the merits and after the filing of a Request for Continued Examination, pursuant to 37 C.F.R. § 1.97(b)(4), no fee is believed to be due.

In the event a fee is due, the Commissioner is authorized to charge any fee deficiency or credit any overpayment to Deposit Account No. 08-0219.

Respectfully submitted,

Dated: April 6, 2004



James T. Olesen, Ph.D.
Registration No. 46,967
Attorney for Applicants

Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
Tel: (617) 526-6045
Fax: (617) 526-5000

HALE AND DORR LLP DRAFT OF MARCH 19, 2004		DOCKET NUMBER 47508.642US2 HYZ-642		APPLICATION NUMBER 09/103,745	
SUBT. FOR, PTO-1449					
INFORMATION DISCLOSURE IN AN APPLICATION (USE SEVERAL SHEETS IF NECESSARY)				APPLICANT AGRAWAL, Sudhir	
				FILING DATE June 24, 1998	
SHEET 1 OF 2				GROUP ART UNIT 1635	

U.S. Patent Documents						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,806,463	2/1989	Goodchild, et al.	514	44	
	5,149,797	9/1992	Pederson, et al.	536	24.5	
	5,194,428	3/1993	Agrawal, et al.	514	44	

Foreign Patent Documents							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	93/13749	7/1993	WIPO				
	94/02498	2/1994	WIPO				
	94/26877	11/1994	WIPO				
	95/09236	4/1995	WIPO				
	96/02555	2/1996	WIPO				
	96/19572	6/1996	WIPO				

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)		
A1	Agrawal (1992) Trends in Biotechnology 10:152-158.	
A2	Agrawal et al (1995) Current Opinion in Biotechnology 6:12-19.	
A3	Agrawal et al. (1995) Clinical Pharmacokinetics 28:7-16.	
A4	Agrawal et al. (1987) Tetrahedron Letters 28:3539-3542.	
A5	Agrawal (1996) Trends in Biotechnology 14:376-387.	
A5	Ballas et al. (1996) Journal of Immunology 157:1840-1845.	
A7	Beaucage, In Protocols for Oligonucleotides and Analogs: Synthesis and Properties, Agrawal (editor), Humana Press, Totowa, NJ, pp.33-61.	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

HALE AND DORR LLP DRAFT OF MARCH 19, 2004 SUBT. FOR, PTO-1449				DOCKET NUMBER 47508.642US2 HYZ-642	APPLICATION NUMBER 09/103,745
INFORMATION DISCLOSURE IN AN APPLICATION <i>(USE SEVERAL SHEETS IF NECESSARY)</i>				APPLICANT AGRAWAL, Sudhir	
				FILING DATE June 24, 1998	GROUP ART UNIT 1635
SHEET	2	OF	2		

A8	Boggs, R. et al, "Characterization and modulation of immuni stimulation by modified oligonucleotides," Antisense & Nucleic Acid Drug Development, Vol. 7, (October 1997), pgs. 461-471.
A9	Dougherty et al. (1992) J. Am. Chem. Soc. 114:6254.
A10	Habus et al. (1996) Bioorganic and Medicinal Chemistry Letters 6:1393-1398.
A11	Iyer et al. (1996) Tetrahedron Letters 37:1539-1542.
A12	Iyer et al. (1995) Nucleosides & Nucleotides 14:1031-1035.
A13	Iyer et al. (1995) Tetrahedron Asymmetry 6:1051-1054.
A14	Kandimalla et al., Nucleic Acids Research, 1997, Vol. 25, No., pp. 370-378.
A15	Krieg et al. (1995) Nature 374:546-549.
A16	Krieg et al. Antisense & Nucleic Acid Drug Devel. 6:133-139 (1996).
A17	Padmapriya et al. (1994) Antisense Research & Development 4:185-189.
A18	Paterson et al. (1977) Proc. Natl. Acad. Sci. USA 74:4370-4374.
A19	Sproat (1995) Journal of Biotechnology 41:221-238.
A20	Stein et al. (1996) Trends in Biotechnology 14:147-149.
A21	Tao et al. (1995) Antisense Research & Development 5:123-129.
A22	Torrence et al. (1993) PNAS 90:1300-1304.
A23	Zamecnik et al. (1978) Proc. Natl. Acad. Sci. USA 75:280-284.
A24	Zhang et al. (1995) Clinical Pharmacology and Therapeutics 58:44-53.
A25	Zhao et al., Biochem. Pharm. 51: 173-182 (1996).
A26	Zhao et al., Antisense & Nucleic Acid Drug Development 7:495-502 (1997).

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	